Ken Griffin Annovis Bio, Inc. Call Options Transaction History

Citadel Advisors LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$5.27 - $15.46 $709,869 - $2.08 Million	-134,700 Reduced 88.33%	17,800 $143,000
Q2 2024 Aug 14, 2024	BUY	$4.82 - $18.01 $309,444 - $1.16 Million	64,200 Added 72.71%	152,500 $878,000
Q1 2024 May 15, 2024	BUY	$8.47 - $18.93 $280,357 - $626,583	33,100 Added 59.96%	88,300 $1.05 Million
Q4 2023 Feb 14, 2024	BUY	$5.55 - $19.62 $306,360 - $1.08 Million	55,200 New	55,200 $1.03 Million

1.17M

229K

934K

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $41.1M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.